-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Analyzing Ignyte Acquisition (NASDAQ:IGNY) and Inhibikase Therapeutics (NYSE:IKT)
Analyzing Ignyte Acquisition (NASDAQ:IGNY) and Inhibikase Therapeutics (NYSE:IKT)
Ignyte Acquisition (NASDAQ:IGNY – Get Rating) and Inhibikase Therapeutics (NYSE:IKT – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, profitability, institutional ownership and valuation.
Earnings & Valuation
This table compares Ignyte Acquisition and Inhibikase Therapeutics' top-line revenue, earnings per share and valuation.
Get Ignyte Acquisition alerts:| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ignyte Acquisition | N/A | N/A | -$490,000.00 | N/A | N/A |
| Inhibikase Therapeutics | $3.10 million | 7.36 | -$14.79 million | ($0.74) | -1.22 |
Ignyte Acquisition has higher earnings, but lower revenue than Inhibikase Therapeutics.
Insider and Institutional Ownership
61.1% of Ignyte Acquisition shares are owned by institutional investors. Comparatively, 13.3% of Inhibikase Therapeutics shares are owned by institutional investors. 55.8% of Inhibikase Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.Risk & Volatility
Ignyte Acquisition has a beta of 0.01, indicating that its stock price is 99% less volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent recommendations and price targets for Ignyte Acquisition and Inhibikase Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ignyte Acquisition | 0 | 0 | 0 | 0 | N/A |
| Inhibikase Therapeutics | 0 | 0 | 0 | 0 | N/A |
Profitability
This table compares Ignyte Acquisition and Inhibikase Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ignyte Acquisition | N/A | 365.46% | -0.83% |
| Inhibikase Therapeutics | -4,894.27% | -48.78% | -44.49% |
Summary
Ignyte Acquisition beats Inhibikase Therapeutics on 5 of the 8 factors compared between the two stocks.
About Ignyte Acquisition
(Get Rating)
Ignyte Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. The company intends to focus on target businesses in the life sciences, biotechnology, and healthcare sectors. Ignyte Acquisition Corp. was incorporated in 2020 and is based in New York, New York.
About Inhibikase Therapeutics
(Get Rating)
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
Receive News & Ratings for Ignyte Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ignyte Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
Ignyte Acquisition (NASDAQ:IGNY – Get Rating) and Inhibikase Therapeutics (NYSE:IKT – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, profitability, institutional ownership and valuation.
納斯達克收購(納斯達克代碼：IGNY-GET)和Inhibikase治療公司(紐約證券交易所代碼：IKT-GET評級)都是小盤醫療公司，但哪一家更好？我們將根據風險的強弱、分析師的建議、收益、股息、盈利能力、機構所有權和估值對這兩家公司進行比較。
Earnings & Valuation
收益與估值
This table compares Ignyte Acquisition and Inhibikase Therapeutics' top-line revenue, earnings per share and valuation.
下表比較了Ignyte收購和Inhibikase治療公司的營收、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ignyte Acquisition | N/A | N/A | -$490,000.00 | N/A | N/A |
| Inhibikase Therapeutics | $3.10 million | 7.36 | -$14.79 million | ($0.74) | -1.22 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| Ignyte收購 | 不適用 | 不適用 | -$490,000.00 | 不適用 | 不適用 |
| 抑制酶療法 | 310萬美元 | 7.36 | -1,479萬元 | ($0.74) | -1.22 |
Ignyte Acquisition has higher earnings, but lower revenue than Inhibikase Therapeutics.
與Inhibikase治療公司相比，Ignyte收購的收益更高，但收入更低。
Insider and Institutional Ownership
內部人與機構持股
Risk & Volatility
風險與波動性
Ignyte Acquisition has a beta of 0.01, indicating that its stock price is 99% less volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500.
Ignyte收購的貝塔係數為0.01，表明其股價的波動性比標準普爾500指數低99%。相比之下，Inhibikase Treeutics的貝塔係數為1.19，這表明其股價的波動性比標準普爾500指數高出19%。
Analyst Ratings
分析師評級
This is a summary of recent recommendations and price targets for Ignyte Acquisition and Inhibikase Therapeutics, as provided by MarketBeat.com.
這是MarketBeat.com提供的Ignyte收購和Inhibikase治療公司最近的建議和目標價摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ignyte Acquisition | 0 | 0 | 0 | 0 | N/A |
| Inhibikase Therapeutics | 0 | 0 | 0 | 0 | N/A |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| Ignyte收購 | 0 | 0 | 0 | 0 | 不適用 |
| 抑制酶療法 | 0 | 0 | 0 | 0 | 不適用 |
Profitability
盈利能力
This table compares Ignyte Acquisition and Inhibikase Therapeutics' net margins, return on equity and return on assets.
下表比較了Ignyte收購和Inhibikase治療公司的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Ignyte Acquisition | N/A | 365.46% | -0.83% |
| Inhibikase Therapeutics | -4,894.27% | -48.78% | -44.49% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| Ignyte收購 | 不適用 | 365.46% | -0.83% |
| 抑制酶療法 | -4,894.27% | -48.78% | -44.49% |
Summary
摘要
Ignyte Acquisition beats Inhibikase Therapeutics on 5 of the 8 factors compared between the two stocks.
與兩隻股票相比，Ignyte收購在8個因素中有5個超過了Inhibikase治療公司。
About Ignyte Acquisition
關於Ignyte收購
(Get Rating)
(獲取評級)
Ignyte Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. The company intends to focus on target businesses in the life sciences, biotechnology, and healthcare sectors. Ignyte Acquisition Corp. was incorporated in 2020 and is based in New York, New York.
Ignyte Acquisition Corp.沒有重大業務。擬與一家或多家企業進行合併、換股、資產收購、股票購買、資本重組、重組或其他類似的業務合併。該公司打算專注於生命科學、生物技術和醫療保健領域的目標業務。Ignyte Acquisition Corp.成立於2020年，總部設在紐約。
About Inhibikase Therapeutics
關於Inhibikase療法
(Get Rating)
(獲取評級)
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
臨牀階段製藥公司Inhibikase Treateutics，Inhibikase Treeutics，Inhibikase Treateutics，Inhibikase Treateutics，Inc.是一家臨牀階段製藥公司，開發帕金森氏病(PD)和大腦內外相關疾病的療法。該公司的候選產品包括用於治療帕金森氏症以及帕金森氏症早期症狀(如吞嚥、吞嚥困難、神經原性便祕和多系統萎縮)的小分子阿貝爾森酪氨酸激酶抑制劑IKT-148009；以及抗癌藥物伊馬替尼的前藥IKT-001Pro，該藥物正處於臨牀前開發階段，旨在將胃腸道副作用降至最低，並用於治療血液和胃癌。它還參與開發其他神經疾病的各種研究計劃。該公司與約翰·霍普金斯大學、亞利桑那州立大學、密歇根州立大學以及路易斯安那州立大學有研發合作。Inhibikase治療公司成立於2008年，總部設在佐治亞州亞特蘭大。
Receive News & Ratings for Ignyte Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ignyte Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
接受Ignyte收購日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Ignyte收購和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧